Anti-inflammatory drugs in epilepsy: Does it impact epileptogenesis?

Expert Opinion on Drug Safety

Volumn 14, Issue 4, 2015, Pages 583-592

  Vezzani, Annamaria ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Animal models of epilepsy; Disease modification; Glia; Neuroinflammation; Neuronal cell loss; Pharmaco resistant epilepsy

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTICONVULSIVE AGENT;

ASTROCYTE; BLOOD BRAIN BARRIER; CELL LOSS; CELL SURVIVAL; EPILEPSY; EPILEPTOGENESIS; GLIA; HUMAN; MICROGLIA; NERVE CELL EXCITABILITY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SEIZURE; SEIZURE SUSCEPTIBILITY; TIGHT JUNCTION; TRANSCRIPTION INITIATION; ANIMAL; DRUG DESIGN; DRUG RESISTANCE; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; ASTROCYTES; DRUG DESIGN; DRUG RESISTANCE; EPILEPSY; HUMANS; INFLAMMATION; MICROGLIA;

EID: 84924982575     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1010508     Document Type: Review

References (82)

1. Pitkanen A, Engel J Jr.Past and present definitions of epileptogenesis and its biomarkers.Neurotherapeutics 2014; 11: 231-41
2. Dudek FE, Staley KJ.The time course and circuit mechanisms of acquired epileptogenesis.2012
3. Pitkanen A, Lukasiuk K.Mechanisms of epileptogenesis and potential treatment targets.Lancet Neurol 2011; 10: 173-86
4. Devinsky O, Vezzani A, Najjar S, et al.Glia and epilepsy: excitability and inflammation.Trends Neurosci 2013; 36: 174-84
5. Filibian M, Frasca A, Maggioni D, et al.In vivo imaging of glia activation using 1H-magnetic resonance spectroscopy to detect putative biomarkers of tissue epileptogenicity.Epilepsia 2012; 53: 1907-16
6. Ravizza T, Boer K, Redeker S, et al.The IL-1beta system in epilepsy-Associated malformations of cortical development.Neurobiol Dis 2006; 24: 128-43
7. Bogdanovic RM, Syvanen S, Michler C, et al.(R)-[11C]PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: evaluation in a rat epilepsy model.Neuropharmacology 2014; 85: 104-12
8. Boer K, Spliet WG, van Rijen PC, et al.Evidence of activated microglia in focal cortical dysplasia.J Neuroimmunol 2006; 173: 188-95
9. Aronica E, Ravizza T, Zurolo E, et al.Astrocyte immune response in epilepsy.Glia 2012; 60: 1258-68
10. Ravizza T, Gagliardi B, Noe F, et al.Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy.Neurobiol Dis 2008; 29: 142-60
11. Dedeurwaerdere S, Callaghan PD, Pham T, et al.PET imaging of brain inflammation during early epileptogenesis in a rat model of temporal lobe epilepsy.EJNMMI Res 2012; 2: 60
12. Vezzani A, Balosso S, Ravizza T.The role of cytokines in the pathophysiology of epilepsy.Brain Behav Immun 2008; 22: 797-803
13. Vezzani A, French J, Bartfai T, et al.The role of inflammation in epilepsy.Nat Rev Neurol 2011; 7: 31-40
14. Marchi N, Granata T, Janigro D.Inflammatory pathways of seizure disorders.Trends Neurosci 2014; 37: 55-65
15. Bauer J, Vezzani A, Bien CG.Epileptic encephalitis: the role of the innate and adaptive immune system.Brain Pathol 2012; 22: 412-21
16. Zattoni M, Mura ML, Deprez F, et al.Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy.J Neurosci 2011; 31: 4037-50
17. Fabene PF, Mora GN, Martinello M, et al A role for leukocyte-endothelial adhesion mechanisms in epilepsy.Nat Med 2008; 14: 1377-83
18. Balosso S, Maroso M, Sanchez-Alavez M, et al A novel non-Transcriptional pathway mediates the proconvulsive effects of interleukin-1beta.Brain 2008; 131: 3256-65
19. Viviani B, Bartesaghi S, Gardoni F, et al.Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases.J Neurosci 2003; 23: 8692-700
20. Iori V, Maroso M, Rizzi M, et al.Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures.Neurobiol Dis 2013; 58: 102-14
21. Maroso M, Balosso S, Ravizza T, et al.Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures.Nat Med 2010; 16: 413-19
22. Balosso S, Liu J, Bianchi ME, et al.Disulfide-Containing High Mobility Group Box-1 Promotes N-Methyl-d-Aspartate Receptor Function and Excitotoxicity by Activating Toll-Like Receptor 4-Dependent Signaling in Hippocampal Neurons.Antioxid Redox Signal 2014; 21: 1726-40
23. Vezzani A, Moneta D, Conti M, et al.Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice.Proc Natl Acad Sci USA 2000; 97: 11534-9
24. Ravizza T, Lucas SM, Balosso S, et al.Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy.Epilepsia 2006; 47: 1160-8
25. Vezzani A, Maroso M, Balosso S, et al.IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures.Brain Behav Immun 2011; 25: 1281-9
26. Sellner J, Trinka E.Clinical characteristics, risk factors and presurgical evaluation of post-infectious epilepsy.Eur J Neurol 2013; 20: 429-39
27. Morin-Brureau M, Lebrun A, Rousset MC, et al.Epileptiform activity induces vascular remodeling and zonula occludens 1 downregulation in organotypic hippocampal cultures: role of VEGF signaling pathways.J Neurosci 2011; 31: 10677-88
28. Balosso S, Ravizza T, Aronica E, et al.The dual role of TNF-Alpha and its receptors in seizures.Exp Neurol 2013; 247C: 267-71
29. Balosso S, Ravizza T, Perego C, et al.Tumor necrosis factor-Alpha inhibits seizures in mice via p75 receptors.Ann Neurol 2005; 57: 804-12
30. Weinberg MS, Blake BL, McCown TJ.Opposing actions of hippocampus TNFalpha receptors on limbic seizure susceptibility.Exp Neurol 2013; 247: 429-37
31. Xiong ZQ, Qian W, Suzuki K, et al.Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration.J Neurosci 2003; 23: 955-60
32. Aronica E, Boer K, van Vliet EA, et al.Complement activation in experimental and human temporal lobe epilepsy.Neurobiol Dis 2007; 26: 497-511
33. Jiang J, Ganesh T, Du Y, et al.Small molecule antagonist reveals seizureinduced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.Proc Natl Acad Sci USA 2012; 109: 3149-54
34. Rojas A, Jiang J, Ganesh T, et al.Cyclooxygenase-2 in epilepsy.Epilepsia 2014; 55: 17-25
35. Jiang J, Dingledine R.Prostaglandin receptor EP2 in the crosshairs of antiinflammation, anti-cancer, and neuroprotection.Trends Pharmacol Sci 2013; 34: 413-23
36. van Vliet EA, Zibell G, Pekcec A, et al.COX-2 inhibition controls Pglycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats.Neuropharmacology 2010; 58: 404-12
37. Bauer B, Hartz AM, Pekcec A, et al.Seizure-induced up-regulation of Pglycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling.Mol Pharmacol 2008; 73: 1444-53
38. Ravizza T, Balosso S, Vezzani A.Inflammation and prevention of epileptogenesis.Neurosci Lett 2011; 497: 223-30
39. Henshall DC, Diaz-Hernandez M, Miras-Portugal MT, et al.P2X receptors as targets for the treatment of status epilepticus.Front Cell Neurosci 2013; 7: 237
40. Mesuret G, Engel T, Hessel EV, et al.P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage.CNS Neurosci Ther 2014; 20: 556-64
41. Auvin S, Shin D, Mazarati A, et al.Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA.Epilepsia 2010; 51(Suppl 3): 34-8
42. Marchi N, Fan Q, Ghosh C, et al.Antagonism of peripheral inflammation reduces the severity of status epilepticus.Neurobiol Dis 2009; 33: 171-81
43. Vezzani A, Conti M, De Luigi A, et al.Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 1999; 19: 5054-65
44. Vezzani A, Balosso S, Ravizza T. Inflammation and epilepsy. Handb Clin Neurol 2012; 107: 163-75
45. Kanner AM, Mazarati A, Koepp M. Biomarkers of epileptogenesis: psychiatric comorbidities (?). Neurotherapeutics 2014; 11: 358-72
46. Vezzani A, Aronica E, Mazarati A, et al. Epilepsy and brain inflammation. Exp Neurol 2013; 244: 11-21
47. Rizzi M, Perego C, Aliprandi M, et al. Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development. Neurobiol Dis 2003; 14: 494-503
48. Marcon J, Gagliardi B, Balosso S, et al. Age-dependent vascular changes induced by status epilepticus in rat forebrain: implications for epileptogenesis. Neurobiol Dis 2009; 34: 121-32
49. Choy M, Dubé CM, Patterson K, et al A novel, noninvasive, predictive epilepsy biomarker with clinical potential. J Neurosci 2014; 34: 8672-84
50. Dubé CM, Ravizza T, Hamamura M, et al. Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers. J Neurosci 2010; 30: 7484-94
51. Friedman A, Dingledine R. Molecular cascades that mediate the influence of inflammation on epilepsy. Epilepsia 2011; 52(Suppl 3): 33-9
52. Steinhauser C, Seifert G, Bedner P. Astrocyte dysfunction in temporal lobe epilepsy: K+ channels and gap junction coupling. Glia 2012; 60: 1192-202
53. Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on excitotoxicity. Neuropharmacology 2014; doi: 10.1016/j. neuropharm.2014.10.027
54. Librizzi L, Noe F, Vezzani A, et al. Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage. Ann Neurol 2012; 72: 82-90
55. Frigerio F, Frasca A, Weissberg I, et al. Long-lasting pro-ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology. Epilepsia 2012; 53: 1887-97
56. Heinemann U, Kaufer D, Friedman A. Blood-brain barrier dysfunction, TGFbeta signaling, and astrocyte dysfunction in epilepsy. Glia 2012; 60: 1251-7
57. Choi J, Nordli DR Jr, Alden TD, et al. Cellular injury and neuroinflammation in children with chronic intractable epilepsy. J Neuroinflammation 2009; 6: 38
58. Mikati MA, Kurdi R, El-Khoury Z, et al. Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature. Epilepsy Behav 2010; 17: 90-4
59. Gayatri N, Ferrie CD, Cross H. Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms. Cochrane Database Syst Rev 2009(3): CD005222
60. Rho JM, Stafstrom CE. The ketogenic diet: what has science taught us?. Epilepsy Res 2012; 100: 210-17
61. Bonaz B, Picq C, Sinniger V, et al. Vagus nerve stimulation: from epilepsy to the cholinergic anti-inflammatory pathway. Neurogastroenterol Motil 2013; 25: 208-21
62. Kossoff EH, Zupec-Kania BA, Rho JM. Ketogenic diets: an update for child neurologists. J Child Neurol 2009; 24: 979-88
63. Klein P, Tyrlikova I, Mathews GC. Dietary treatment in adults with refractory epilepsy: a review. Neurology 2014; 83: 1978-85
64. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5: 553-64
65. Vezzani A, Balosso S, Maroso M, et al. ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Curr Opin Investig Drugs 2010; 11: 43-50
66. Cornelis S, Kersse K, Festjens N, et al. Inflammatory caspases: targets for novel therapies. Curr Pharm Des 2007; 13: 367-85
67. Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1006-12
68. Fleishmann RM. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-Alpha agents. Clin Exp Rheumatol 2002; 20: S35-41
69. Varvel NH, Jiang J, Dingledine R. Candidate drug targets for prevention or modification of epilepsy. Annu Rev Pharmacol Toxicol 2015; 55: 229-47
70. Noe FM, Polascheck N, Frigerio F, et al. Pharmacological blockade of IL-1beta/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis 2013; 59: 183-93
71. Clausen F, Hanell A, Bjork M, et al. Neutralization of interleukin-1beta modifies the inflammatory response and improves histological and cognitive outcome following traumatic brain injury in mice. Eur J Neurosci 2009; 30: 385-96
72. Ma L, Cui XL, Wang Y, et al. Aspirin attenuates spontaneous recurrent seizures and inhibits hippocampal neuronal loss, mossy fiber sprouting and aberrant neurogenesis following pilocarpineinduced status epilepticus in rats. Brain Res 2012; 1469: 103-13
73. van Vliet EA, Aronica E, Gorter JA. Blood-brain barrier dysfunction, seizures and epilepsy. Semin Cell Dev Biol 2014; doi: 10.1016/j.semcdb.2014.10.003
74. Giza CC, Kolb B, Harris NG, et al. Hitting a moving target: basic mechanisms of recovery from acquired developmental brain injury. Dev Neurorehabil 2009; 12: 255-68
75. Simonato M, Brooks-Kayal AR, Engel J Jr, et al. The challenge and promise of anti-epileptic therapy development in animal models. Lancet Neurol 2014; 13: 949-60
76. Vezzani A, Friedman A. Brain inflammation as a biomarker in epilepsy. Biomark Med 2011; 5: 607-14
77. Hirvonen J, Kreisl W, Fujita M, et al. Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy. American Epilepsy Society, S Antonio (TX) 2010; abstract 3230
78. Harhausen D, Sudmann V, Khojasteh U, et al. Specific imaging of inflammation with the 18 kDa translocator protein ligand DPA-714 in animal models of epilepsy and stroke. PLoS One 2013; 8: e69529
79. Nag S, Lehmann L, Kettschau G, et al. Synthesis and evaluation of [(1)(8)F] fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B). Bioorg Med Chem 2012; 20: 3065-71
80. Gauberti M, Montagne A, Quenault A, et al. Molecular magnetic resonance imaging of brain-immune interactions. Front Cell Neurosci 2014; 8: 389
81. Duffy BA, Choy M, Riegler J, et al. Imaging seizure-induced inflammation using an antibody targeted iron oxide contrast agent. Neuroimage 2012; 60: 1149-55
82. Kobow K, Blumcke I. Epigenetic mechanisms in epilepsy. Prog Brain Res 2014; 213: 279-316